---
title: "RemeGen Clarifies Board Composition and Committee Roles"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/289936377.md"
description: "RemeGen Co. Ltd. (HK:9995) announced its board composition, featuring five executive directors, one non-executive director, and three independent non-executive directors, with Wang Weidong as chairman. The company also detailed membership and chairperson roles for its Audit, Remuneration and Appraisal, Nomination, and Strategy committees to reinforce corporate governance. This disclosure highlights RemeGen's commitment to structured oversight and regulatory compliance in the biopharmaceutical sector."
datetime: "2026-06-16T14:39:30.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/289936377.md)
  - [en](https://longbridge.com/en/news/289936377.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/289936377.md)
generator: "portal-rs"
---

# RemeGen Clarifies Board Composition and Committee Roles

The latest announcement is out from RemeGen Co. Ltd. Class H ( (HK:9995) ).

RemeGen Co., Ltd. has disclosed the current composition of its board of directors, which includes five executive directors, one non-executive director, and three independent non-executive directors, with Wang Weidong serving as chairman. The company also detailed the membership and chairperson roles across its four key board committees—Audit, Remuneration and Appraisal, Nomination, and Strategy—clarifying governance responsibilities and reinforcing its corporate oversight structure.

The announcement underscores RemeGen’s emphasis on formal governance and committee-based oversight, which is important for investors tracking board independence and accountability in a regulated biopharmaceutical market. By clearly allocating leadership roles and committee memberships, the company signals a structured decision-making framework that may support regulatory compliance, risk management, and strategic execution for stakeholders.

The most recent analyst rating on (HK:9995) stock is a Buy  
 with a HK$129.00 price target.  
 To see the full list of analyst forecasts on RemeGen Co. Ltd. Class H stock,  
 see the HK:9995 Stock Forecast page. 

**More about RemeGen Co. Ltd. Class H**

RemeGen Co., Ltd. is a joint stock company incorporated in the People’s Republic of China and listed in Hong Kong under stock code 9995. The company operates in the biopharmaceutical sector, focusing on developing and commercializing innovative therapies, and targets both domestic and international healthcare markets.

**Average Trading Volume:** 4,309,466

**Technical Sentiment Signal:** Buy

**Current Market Cap:** HK$62.15B

Find detailed analytics on 9995 stock on TipRanks’ Stock Analysis page.

### Related Stocks

- [09995.HK](https://longbridge.com/en/quote/09995.HK.md)
- [688331.CN](https://longbridge.com/en/quote/688331.CN.md)

## Related News & Research

- [RemeGen files HKEX next-day disclosure return reporting share buyback on Shanghai exchange at RMB 113.43 per share](https://longbridge.com/en/news/298706225.md)
- [RemeGen Deploys Idle Funds Into Discloseable Wealth Management Products](https://longbridge.com/en/news/297779978.md)
- [UBS Reaffirms Their Buy Rating on NIO Inc. Class A (9866)](https://longbridge.com/en/news/298690881.md)
- [Premium Income files ATM equity program for up to CAD 250 million in preferred, Class A shares](https://longbridge.com/en/news/298317421.md)
- [Weekly Recap: Xiaomi Class B price hikes and Class B share repurchase](https://longbridge.com/en/news/298142637.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**